Login to Your Account

Intercept shares hit headwinds despite solid earnings and clinical success

By Marie Powers
News Editor

Monday, July 31, 2017

Intercept Pharmaceuticals Inc. reported $30.4 million in second-quarter global net sales of Ocaliva (obeticholic acid, or OCA), beating consensus estimates of $26 million to $27 million.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription